[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100542710":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":12,"locations":18,"responsibleParty":35,"collaborators":7,"id":39,"slug":40,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":41,"sex":47,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":7,"studyType":53,"phases":7,"briefSummary":54,"conditions":55,"keywords":7,"overallStatus":21,"whyStopped":7,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":66},{"fullName":5,"class":6},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","OTHER",null,[9],{"type":6,"name":10,"description":11,"armGroupLabels":7,"otherNames":7},"Subthreshold Micropulse Laser Treatment","Subthreshold micropulse laser treatment consists in 33 spots of 100 microns, distance among each spot of 2.50 microns, duration of 200 sec, power of 250 milliwatt (mW) duty cycle 5%.",[13],{"name":14,"role":15,"phone":16,"phoneExt":7,"email":17},"Maria Cristina Savastano, MD, PhD","CONTACT","(+39)063015","mariacristinasavastano@policlinicogemelli.it",[19],{"facility":20,"status":21,"city":22,"state":23,"zip":24,"country":25,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"Fondazione Policlinico Agostino Gemelli, IRCCS","RECRUITING","Roma","R","00168","Italy","IT",{"type":28,"coordinates":29},"Point",[30,31],11.10642,44.99364,{"lat":31,"lon":30},[34],{"name":14,"role":15,"phone":16,"phoneExt":7,"email":17},{"type":36,"investigatorFullName":37,"investigatorTitle":38,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Savastano Maria Cristina","Principal Investigator","100542710","central-serous-chorioretinopathy-and-micropulse-laser-treatment-100542710",false,"NCT06346405","Central Serous Chorioretinopathy and Micropulse Laser Treatment","Central Serous Chorioretinopathy and Micropulse Laser Treatment: Evaluation of Morphological and Functional Recovery","LEVEO","Inclusion Criteria:\n\n* Diagnosis of central serous chorioretinopathy (CSC) with no response to conservative therapy, consisted in Acetazolamide and Eplerenone after six months.\n* Foveal serous retinal detachment for at least 6 months.\n* Minimum age of 18 years old at the screening time\n* Reading and comprehension skills of informed consent\n\nExclusion Criteria:\n\n* Previous retinal treatment for CSC, except for Acetazolamide and Eplerenone\n* No diffuse retinal epitheliopathy\n* Other concomitant ocular diseases, such as age related macular degeneration, diabetic retinopathy, choroidal neovascularization\n* Not controlled glaucoma with eyedrops, or advanced glaucoma\n* Myopia or hypermetropia greater than 6 diopters\n* Opacities of dioptric media\n* Low quality of optical coherence tomography (OCT) and OCT-Angiography scans\n* Low quality images of Fluorescein angiography and indocyanine green angiography\n* No written consensus signed.","ALL","18 Years","70 Years",{"count":51,"type":52},36,"ESTIMATED","OBSERVATIONAL","To evaluate choroidal and choriocapillaris changes in patients with central serous chorioretinopathy, undergone sub threshold micropulse laser treatment, following any improvement with conservative therapy with Acetazolamide and\u002For Eplerenone",[56],"Central Serous Chorioretinopathy","2025-09-17",{"date":59,"type":60},"2025-09-23","ACTUAL",{"date":62,"type":60},"2023-05-31",{"date":64,"type":52},"2027-05-31",{"name":5,"class":6},1]